A pharmaceutical company requires much more than just one source for the identification of names for compounds. Right from the discovery of the compounds through validation of targets to safety evaluation, research, digital health, etc., accurate data could lead to quick and better decision-making.
This is the rationale behind the comparison of alternatives to DrugBank by companies that require extra compound coverage and improved assays among others. There are no good DrugBank alternatives that directly replace DrugBank, anyway. In most cases, they complement each other in a research stack.
The online database of drugs may be very good for the structural information but poor for labeling information. A database of drug information may help with drug research and safety assessment but may lack the information at the level of assay that is required for drug discovery.
There is no single piece of software that can provide everything needed in developing pharmaceutical products. One set of people might be in need of target and assay data, whereas another group of people would need labeling and safety information about the drug.
Common reasons researchers compare platforms include:
In fact, many groups combine databases, rather than try to substitute one database for another.

In choosing an online drug database for your research, always remember to consider your needs first. Big names don’t always make the best choice.
Evaluate each resource for:
The best research stack is one that helps you manage your data better, not worse.
They all serve a purpose. Judge these databases based on what you need from them, and not only their name.
Ideal for: Structures of chemicals, discovery of compounds, and public chemical information.
PubChem provides an extensive database for investigating chemicals, identification numbers, properties, bioactivity relationships, and relevant literature about them. It comes highly recommended whenever it is necessary for teams to investigate, compare, and organize chemicals during early stages of research.
Ideal match: Early discovery, cheminformatics, academic research, and chemicals investigation.
Consideration: You may require other resources to find clinical and medication-related information.
Recommended for: Bioactivity data, assays, targets and medicinal chemistry studies.
ChEMBL is extensively used for bioactivity data. It is useful for researchers who want to learn about the relationship between a compound and its target and more information about an assay.
Recommended for: Medicinal chemistry, drug discovery, screening, and computational chemistry.
Not recommended for: Information on medications.
Best for: Drug-centric research connecting medications, indications, pharmacology, and targets.
DrugCentral supports research that sits between drug discovery and clinical application. It can be helpful when teams want to examine approved drugs alongside their targets, indications, and pharmacological context.
Best fit: Translational research, indication analysis, and drug repurposing projects.
Watch-out: Pair it with label-focused or real-world data sources when deeper clinical context is required.
Best for: Protein-ligand binding data and target-focused research.
BindingDB gives researchers access to binding affinity data that supports the study of drug-target interactions. It is valuable for computational modeling, pharmacology, and target identification.
Best fit: Target research, molecular modeling, and computational drug discovery.
Watch-out: Its focus is narrower than a broader clinical or medication-management database.
Best for: Therapeutic targets, disease relationships, and target validation.
TTD connects therapeutic targets with diseases and therapeutic agents. It can help researchers move from a disease-area question toward potential biological targets and treatment pathways.
Best fit: Target prioritization, indication research, and early therapeutic strategy.
Watch-out: It works best alongside assay, chemistry, or bioactivity databases.
Best for: Evidence-based target-disease association and target prioritization.
Open Targets brings together genetics, omics, scientific literature, and disease evidence to help teams assess the strength of a target-disease relationship.
Best fit: Precision medicine, biomarker development, genetics-led discovery, and target selection.
Watch-out: It is target-focused, not a complete medication reference database.
Best for: Pharmacogenomics and gene-drug relationships.
PharmGKB is designed for teams exploring how genetic variation may influence drug response. It includes pharmacogenetic annotations, variant associations, and clinical-guidance context.
Best fit: Personalized medicine, pharmacogenomics, and drug-response research.
Watch-out: It is specialized and should not be treated as a comprehensive drug discovery resource.
Best for: Medication labeling, dosage, warnings, and safety-related reference content.
DailyMed provides structured prescribing information that can support label review, regulatory research, and clinical content validation. It is especially useful for checking official medication information.
Best fit: Regulatory research, clinical content teams, and label validation.
Watch-out: Use other sources for deep bioactivity, pathway, or target research.
Best for: Medication naming, normalization, and interoperability.
RxNorm standardizes medication concepts and helps map brand and generic names. This is essential when research data comes from multiple systems, medication lists, EHRs, pharmacy tools, or datasets.
Best fit: Data normalization, healthcare integration, and medication-list standardization.
Watch-out: RxNorm is a terminology resource, not a full research knowledge base.
Best for: Integrated pharmaceutical research data, APIs, and workflow-ready access.
The DrugsVault platform assists drug companies seeking scalable access to drug data, interactions, allergy data, clinical APIs, and research-ready data sets. It is designed for drug companies that require data to go beyond the browser-based research process into connected solutions.
Best fit: Pharmaceutical research, clinical applications, EHR integration, telehealth, and data-driven digital-health workflows.
Watch-out: Evaluate API coverage, licensing rights, update cadence, and required fields against your specific project before implementation.
| Database | Best For | Target/Pathway Data | Bioactivity/Assays | Clinical/Label Context | API or Bulk Access | Use Considerations |
|---|---|---|---|---|---|---|
| PubChem | Compound discovery | Moderate | Moderate | Limited | Yes | Strong public resource |
| ChEMBL | Assays and bioactivity | Strong | Strong | Limited | Yes | Ideal for discovery research |
| DrugCentral | Drug-centric research | Strong | Moderate | Moderate | Available | Good translational fit |
| BindingDB | Binding affinity | Strong | Strong | Limited | Yes | Target-focused |
| TTD | Target prioritization | Strong | Limited | Moderate | Varies | Pair with chemistry data |
| Open Targets | Target-disease evidence | Strong | Limited | Limited | Yes | Precision medicine focus |
| PharmGKB | Pharmacogenomics | Moderate | Limited | Strong | Available | Specialized scope |
| DailyMed | Labels and safety | Limited | Limited | Strong | Yes | Official label reference |
| RxNorm | Medication normalization | Limited | Limited | Moderate | Yes | Terminology and mapping |
| DrugsVault | Connected data workflows | Varies | Varies | Strong | API-ready | Review licensing and coverage |
You should not think about the database name first but rather the problem first.
What kind of information do you need from your database? Target, assay, interaction, label, genetic, adverse event, drug nomenclature, or API. Then try the database out with testing data.
You should:
APIs make drug data usable beyond a research browser. They allow teams to connect medication intelligence to dashboards, internal databases, research apps, clinical tools, and analytics workflows.

Key benefits include:
In many cases, the best strategy involves leveraging both the public source information context and curated internal or commercial data, through clear governance and a common medication data model.
The best option depends on your use case. PubChem and ChEMBL are strong for compounds and bioactivity, Open Targets and TTD support target prioritization, DailyMed supports labeling research, and RxNorm helps with medication normalization.
Yes. Resources such as PubChem, ChEMBL, Open Targets, PharmGKB, DailyMed, and RxNorm are commonly used in academic and public research. Always confirm the current data-use terms before downloading, redistributing, or commercializing information.
Browser access may be enough for early exploration. APIs become important when teams need repeatable lookups, automated updates, large-scale analysis, connected applications, or standardized data across multiple systems.
Compare DrugBank alternatives based on your research goals, whether you need target data, bioactivity, pharmacogenomics, labeling, or API-ready drug intelligence.